The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...

Antibody fragments have also been developed ... embody the growing diversity of recombinant biologic therapeutics that draw on protein domains from any source. Advances in technology have driven ...

The structure of the ROR1-binding arm of the bi-specific antibody in complex with ROR1 was determined by X-ray crystallography. Disclaimer: AAAS and EurekAlert! are not responsible for the ...

Antibodies serve a purpose in your body ... for the amount of time the clinician recommends following the blood draw. The discomfort should disappear in a day or two. On a rare occasion, a ...